The purpose of this post approval study (PAS) is to evaluate the safety of the long-term use of the OPTIMIZER Smart device and Cardiac Contractility Modulation therapy on the quality of life and heart failure symptoms for patients who remain symptomatic despite optimized guideline directed heart failure medications.
View on ClinicalTrials.gov, Impulse-Dynamics, and FDA.gov or call the Reading Hospital Research Office at 484-628-8585 for more information.
